EGFR and non-small cell lung carcinoma: Amivantamab-vmjw presents a novel mechanism as a bispecific EGFR and mesenchymal epithelial transition (MET) receptor antibody with accelerated FDA approval in May 2021 for patients with metastatic NSCLC with EGFR exon20ins mutations who have progressed after platinum-based chemotherapy [15].